Regression and Stabilization of Coronary Vulnerable Plaque by Evolocumab as Assessed by Multidetector Row Computed Tomography

Intern Med. 2020 Oct 1;59(19):2391-2395. doi: 10.2169/internalmedicine.4436-20. Epub 2020 Jun 30.

Abstract

A 65-year-old man was followed for his coronary conditions using 320-multi detector row computed tomography (MDCT) for 30 months. He had soft plaque in the right coronary artery (RCA) [mean density of plaque was 22 hounsfield units (HU)]. His initial serum low-density lipoprotein cholesterol (LDL-C) was 72 mg/dL. After 30 months, his serum LDL-C was 26 mg/dL under 5.0 mg/day rosuvastatin and evolocumab 140 mg/2 weeks. MDCT showed a regression of the plaque in the RCA and the plaque density was 114 HU (intermediate plaque). In conclusion, intensive lipid-lowering therapy with evolocumab induced the regression and stabilization of coronary vulnerable plaque.

Keywords: PCSK9; evolocumab; multidetector row computed tomography; myocardial infarction; plaque.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Coronary Artery Disease / drug therapy*
  • Coronary Vessels / diagnostic imaging*
  • Humans
  • Male
  • Multidetector Computed Tomography / methods
  • Plaque, Amyloid / diagnostic imaging*
  • Plaque, Atherosclerotic / chemically induced*
  • Plaque, Atherosclerotic / diagnosis*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized